Insulin aspart, recombinant Subcutaneous and Mogamulizumab
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Mogamulizumab and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: mogamulizumab
Brand name: Poteligeo
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Mogamulizumab-kpkc
- Insulin aspart, recombinant Subcutaneous-Mogamulizumab-kpkc Intravenous
- Insulin aspart, recombinant Subcutaneous-Molindone
- Insulin aspart, recombinant Subcutaneous-Mometasone (Oral Inhalation)
- Insulin aspart, recombinant Subcutaneous-Mometasone and Formoterol
- Insulin aspart, recombinant Subcutaneous-Mometasone and formoterol Inhalation
- Mogamulizumab-Insulin degludec
- Mogamulizumab-Insulin Degludec (U-100) Prefilled Pens
- Mogamulizumab-Insulin Degludec (U-100) Vials
- Mogamulizumab-Insulin Degludec (U-200) Prefilled Pens
- Mogamulizumab-Insulin degludec and liraglutide
- Mogamulizumab-Insulin degludec and liraglutide Subcutaneous